|
|
VGX
Animal Health Announces Promotion of Kevin W. Rassas to President
|
| The
Woodlands, TX – November 7, 2007 – |
|
VGX Animal Health, Inc. (VGXAH),
a leading developer of cutting edge technologies for animal health applications,
today announced the promotion of Kevin W. Rassas to President. The Company
was formed in May 2007 as a subsidiary of VGX Pharmaceuticals, Inc. (VGXP).
Mr. Rassas joined VGXAH in May 2007 as Senior Vice President. Mr. Rassas
has over 30 years of pharmaceutical industry experience, including senior
level general management responsibility at Searle and Wyeth. He has a
strong strategic and operational focus with a proven track record of delivering
solid revenue growth and bottom line results. Mr. Rassas has played a
major role in the integration of large and complex businesses and has
instituted numerous programs to improve operating efficiencies. His background
includes significant experience in International Operations P&L Management,
Strategic Planning, Business Development, Finance and Administration,
New Product Introductions and Joint Ventures. He will continue to be Senior
Vice President, Business Development at VGX Pharmaceuticals, which he
joined in 2003.
Dr. J. Joseph Kim, President and CEO of VGX Pharmaceuticals, will remain
on VGX Animal Health as Chairman. Dr. Kim stated, “Kevin has displayed
exceptional leadership since the formation of VGX Animal Health. I am
certain that Kevin will continue to utilize his extensive industry experience
and leadership skills to manage VGX Animal Health’s overall strategy
to become a dynamic global biopharmaceutical company for animal health
applications.”
Mr. Rassas received a Bachelor of Arts in Economics from the University
of Notre Dame and an MBA in Finance from the Kellogg School of Management
at Northwestern University.
Cautionary Factors That May Affect Future
Results - Materials in this Web site contain information
that includes or is based upon forward-looking statements within the
meaning of the Securities Litigation Reform Act of 1995. Forward-looking
statements relate to expectations or forecasts of future events. You
can identify these statements by the fact that they do not relate
strictly to historical or current facts. They use words such as "anticipate,"
"estimate," "expect," "project," "intend,"
"plan," "believe," and other words and terms of
similar meaning in connection with a discussion of potential future
events, circumstances or future operating or financial performance.
In particular, these include statements relating to future actions,
prospective products or product approvals, future performance or results
of current and anticipated products, sales efforts, expenses, the
outcome of contingencies such as legal proceedings, and financial
results. Any or all of our forward-looking statements here or in other
publications may turn out to be wrong. They can be affected by inaccurate
assumptions or by known or unknown risks and uncertainties. Many such
factors will be important in determining our actual future results.
Consequently, no forward-looking statement can be guaranteed, and
forward-looking statements may be adversely affected by factors, including
general market conditions, competitive product development, product
availability, current and future branded and generic competition,
federal and state regulations and legislation, manufacturing issues,
timing of the elimination of trade buying, patent positions, litigations
and investigations. Our actual results may vary materially, and there
are no guarantees about the performance or valuation of VGX stock.
It is also important to read the disclosure notice contained in many
of the individual VGX documents available on this Web site as many
contain important information on such cautionary factors as of the
date of the individual document. We undertake no obligation to correct
or update any forward-looking statements, whether as a result of new
information, future events or otherwise. You are advised, however,
to consult any further disclosures we make on related subjects in
our reports. |
About VGX Animal Health
VGX Animal Health, Inc. (“VGXAH” or “The Company”)
was formed in 2007 as a majority-owned subsidiary of VGX Pharmaceuticals,
Inc. (VGXP) specializing in animal health therapeutics. VGXAH’s products
and technology were initially developed by ADViSYS Inc, which was founded
in 1997 and acquired by VGX Pharmaceuticals in early 2007. VGXAH’s
lead product, LifeTide SW™ 5, is undergoing final regulatory review
in Australia, and is expected to receive approval in Q1 2008. The product
is an injectable plasmid encoding for the production of porcine Growth Hormone
Release Hormone (“GHRH”). In addition, the Company has conducted
extensive pre-clinical trials for other applications of its proprietary
plasmid-based GHRH therapy in both food and companion animals. Treatment
of cancer cachexia, anemia, and improved milk production are just a few
of the many potential applications of this technology in animal health.
VGXAH’s product candidates and technology programs are protected by
the Company's extensive global intellectual property portfolio. More information
about VGXAH can be found at www.vgxah.com.
About VGX Pharmaceuticals
VGX Pharmaceuticals is a biopharmaceutical company with small molecules
and biologics product candidates for the treatment of infectious diseases,
cancer and inflammatory diseases. The Company’s clinical development
programs include PICTOVIR™ for HIV infection and VGX-410C for chronic
HCV infection, both of which are currently in Phase II clinical trials.
In addition, Phase I clinical trials will be initiated in 2007 for VGX-150
for the treatment of Melanoma and VGX-1027 for inflammatory diseases. VGX’s
research pipelines include new generation of DNA vaccines and therapeutics
as well as CELLECTRA™, a proprietary DNA delivery device. The product
candidates and technology programs are protected by the Company’s
extensive global intellectual property portfolio. More information about
VGX can be found at www.vgxp.com.
Company Contact:
Doug Kern, DVM, MS
Vice President, Business Development
Tel. 281-296-7300
Fax. 281-296-7333
E-mail: dkern@vgxah.com
www.vgxah.com
|
